Scancell Holdings (GB:SCLP) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
In a strategic move, Scancell Holdings has appointed Dr. Phil L’Huillier as the new CEO, bringing his extensive experience in the pharmaceutical industry to bolster the company’s efforts in pioneering cancer immunotherapies. This leadership change aims to leverage Scancell’s innovative platforms, ImmunoBody® and Moditope®, to advance their clinical trials and potentially enhance investor value. Former CEO Professor Lindy Durrant will remain as Chief Scientific Officer, continuing to support the company’s scientific endeavors.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
